New therapies for chronic obstructive pulmonary disease

Thorax

Volumn 53, Issue 2, 1998, Pages 137-147

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 1 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 1 PHENYL 2 (4 PYRIDYL)ETHANE; 2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 4 CYANO 4 [3 CYCLOPENTYLOXY 4 METHOXY PHENYL] 1 CYCLOHEXANECARBOXYLIC ACID; 7 [3 [2 CYCLOPROPYLMETHYL 3 METHOXY 4 [(METHYLAMINO)CARBONYL]PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 PROPANOIC ACID; ANTIOXIDANT; ATIZORAM; ATROPINE; BRONCHODILATING AGENT; BUTAPROST; CLARITHROMYCIN; CORTICOSTEROID; DARIFENACIN; ERYTHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 8; IPRATROPIUM BROMIDE; LEUKOTRIENE B4; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MACROLIDE; MISOPROSTOL; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN DERIVATIVE; REVATROPATE; ROXITHROMYCIN; SB 201146; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BETA ADRENERGIC STIMULATION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFICACY; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION;

EID: 0031898818     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.53.2.137     Document Type: Review

References (139)

1. Murray CJL, Lopez A. Evidence based health policy: lessons from the global burden of disease. Science 1996; 274:740-3.
2. 1. JAMA 1994;272:1497-505.
3. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996;110:62-70.
4. Barnes PJ. Muscarinic receptor subtyes in airways. Life Sci 1993;52:521-8.
5. Patel HJ, Barnes PJ, Takahashi T, Tadjkarimi S, Yacoub MH, Belvisi MG. Characterization of prejunctional muscarinic autoreceptors in human and guinea-pig trachea in vitro. Am J Respir Crit Care Med 1995;152:872-8.
6. 3 antagonists for clinical use. Life Sci 1997;60:1053-60.
7. Disse B, Reichal R, Speck G, Travnecker W, Rominger KL, Hammer R. Ba679BR, a novel anticholinergic bronchodilator: preclinical and clinical aspects. Life Sci 1993;52:537-44.
8. Barnes PJ, Belvisi MG, Mak JCW, Haddad E, O'Connor B. Tiotropium bromide (Ba 670 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sci 1995;56:853-9.
9. Haddad E, Mak JCW, Barnes PJ. Characterization of [3H]Ba 679, a slow-dissociating muscarinic receptor antagonist in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994;45:899-907.
10. Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea-pig and human airways. Am J Respir Crit Care Med 1994;150:1640-5.
11. O'Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;154:876-80.
12. Maesen FPV, Smeets JJ, Costongs MAL, Wald FDM, Cornelissen PJG. BA 679 Br, a new long-acting antimuscarinic bronchodilator; a pilot dose-escalation study. Eur Respir J 1993;6:10316.
13. Maesen FPV, Smeets JJ, Sledsens TJM, Wald FDM, Cornelissen JPG. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1995;8:1506-13.
14. Littner M, Auerbach D, Campbell S, et al. The bronchodilator effects of tiotropium bromide in stable COPD. Am J Respir Crit Care Med 1997;155:A282.
15. Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre, randomised, double blind, placebo controlled crossover study. Thorax 1995;50:750-4.
16. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-21.
17. Cazzola M, Matera MG, Santangelo G, Vinciguerra A, Rossi F, D'Amato G. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995;89:357-62.
18. Anderson W, Wisniewski M, Barbee R, Rickard K. A comparison of Serevent and ipratropium on pulmonary function in COPD patients reversible to ipratropium. Am J Respir Crit Care Med 1997;155:A277.
19. Silagy C, Mint D, Fowler G, Ludge M. Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994;343:139-42.
20. Foulds J. Strategies for smoking cessation. Br Med Bull 1996;52:157-73.
21. Schneider NO, Olmstead RE, Steinberg C, Sloan K, Daims RM, Brown HV. Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Clin Pharmacol Ther 1996;60:568-75.
22. Lief HI. Bupropion treatment of depression to assist smoking cessation. Am J Psychiatry 1996;153:442.
23. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202.
24. Thompson PB, Daughton D, Robbins GA, Ghafouki MA, Oehlerking M, Rennard SI. Intramural airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-37.
25. Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147:301-6.
26. Bosken CM, Hards J, Gatter X, Hogg JC. Characterization of the inflammatory reaction on the peripheral airways of cigarette smokers using immunocyctochemistry. Am Rev Respir Dis 1992;145:911-7.
27. Mueller R, Chanez P, Campbell AM, Bousquet J, Heusser C, Bullock GR. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. Respir Med 1996;90:79-85.
28. 1. Am J Respir Crit Care Med 1997; 155:852-7.
29. Lacoste JY, Bousquet J, Chanez P. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis and chronic obstructive pulmonary disease. J Allergy Clin Immunol 1993;92:537-48.
30. Saetta M, Distefano A, Maestrelli P, et al. Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med 1994;150:1646-52.
31. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995;152:1262-7.
32. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
33. Finkelstein R, Fraser RS, Ghezzo H, Cosio MG. Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 1995;152:1666-72.
34. Kwon OJ, Au BT, Collins PD, et al. Tumor necrosis factor-induced interleukin 8 expression in cultured human epithelial cells. Am J Physiol 1994;11:L398-405.
35. Barnes PJ, Karin M. Nuclear factorκB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
36. 4 in the human lung, recruitment of neutrophils into the alveolar spaces without a change in protein permeability. J Clin Invest 1989;84: 1609-19.
37. Zakrzewski JT, Barnes NC, Costello JF, Piper PJ. Lipid mediators in cystic fibrosis and chronic obstructive pulmonary disease. Am Rev Respir Dis 1987;136:779-82.
38. 4 by alveolar macrophages. J Clin Invest 1991;88:891-7.
39. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest 1997; 111:732-43.
40. Renkema TE, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109:1156-62.
41. Pauwels RA, Löfdahl C, Pride NB, Postma DS, Laitinen LA, Ohlsson SV. European Respiratory Society study on chronic obstructive pulmonary disease (EUROSCOP): hypothesis and design. Eur Respir J 1992;5:1254-61.
42. Llewellyn Jones CG, Harris TA, Stockley RA. Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Am J Respir Crit Care Med 1996;153:616-21.
43. Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997;155:542-8.
44. Claman DM, Boushey HA, Liu J, Wong H, Fahy JV. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J Allergy Clin Immunol 1994;94:861-9.
45. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996;154:407-12.
46. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet 1997;349:490-5.
47. Kwon OJ, Au BT, Collins PD, et al. Inhibition of interleukin-8 expression in human cultured airway epithelial cells. Immunology 1994;81:389-94.
48. Barnes PJ, Adcock IM. NF-κB: a pivotal role in asthma and a new target for therapy. Trends Pharmaeol Sci 1997; 18:46-50.
49. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of diuretic monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
50. 4 antagonist LY293111 on allergen-induced responses in asthma. Thorax 1996;51:1178-84.
51. Frenette PS, Wagner DD. Adhesion molecules Pan II: Blood vessels and blood cells. N Engl J Med 1996;335: 43-5.
52. Di Stefano A, Maestrelli P, Roggen A, et al. Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 1994;149:803-10.
53. Nielson CP, Vestal RE, Sturm RJ, Heasli PR. Effect of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 1990;86:801-8.
54. Schudt C, Winder S, Forderkunz S, Hatzelmann A, Ullrich V. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cai. Naunyn Schmiedeberg's Arch Pharmacol 1991;344:682-90.
55. Bloemen PG, van den Tweel MC, Henricks PA, et al. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells. Am J Physiol 1997;272:L580-7.
56. Muller T, Engels P, Fozard J. Subtypes of the type 4 cAMP phosdphodiesterase: structure, regulation and selective inhibition. Trend Pharmacol Sci 1996;17:294-8.
57. 2-agonists and methylxanthines on neutrophil function in vitro. Eur Respir J 1994;7:1460-6.
58. Culpitt S, Maziak W, Loukides S, Keller A, Barnes PJ. Effect of theophylline on induced sputum inflammatory indices in COPD patients. Am J Respir Crit Care Med 1998;157 (in press).
59. Dent G, Giembycz MA, Rabe KF, Wolf B, Barnes PJ, Magnussen H. Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am J Respir Cell Mol Biol 1994;10:565-72.
60. Tenor H, Hatzelmann A. Kupferschmidt R, et al. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy 1995;25: 625-33.
61. Talpain E, Armstrong RA, Coleman RA, Vardey CJ. Characterization of the PGE receptor subtype mediating inhibition of superoxide production in human neutrophils. Br J Pharmacol 1995;114:1459-65.
62. Cohen AB, Girard W, Mclarty J, et al. A controlled trial of colchicine to reduce the elastase load in the lungs of cigarette smokers with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990;142:63-72.
63. Sanchez CW, Lavietes MH, Pokomey ES. Effect of colchicine on pulmonary function. Am J Respir Crit Care Med 1997;155:A282.
64. Anderson R, Theron AJ, Feldman C. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils. Inflammation 1996;20:693-705.
65. Ichikawa Y, Ninomiya H, Koga H, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992;146:196-203.
66. Hohlfeld J, Fabel H, Hamm H. The role of pulmonary surfactant in obstructive airways disease. Eur Respir J 1997;10:482-91.
67. Oetomo SB, Lewis J, Ikegami M, Jobe AH. Surfactant treatments after endogenous surfactant metabolism in rabbit lungs. J Appl Physiol 1990;68:1590-6.
68. Lusuardi M, Capelli A, Salmona M, Tacconi MT, Cerutti CG, Donner CF. Intraluminal inflammation in the airways of patients with chronic bronchitis after treatment with Ambroxol. Monaldi Arch Chest Dis 1995;50:346-51.
69. Stockley RA. The role of proteninases in the pathogenesis of chronic bronchitis. Am J Respir Crit Care Med 1994; 150:S109-13.
70. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990;85:682-9.
71. Nakamura H, Yoshimura K, McElvaney NG, Crystal RG. Neutrophil elastase in respiratory epithelial lining fluid of individuals with cystic ribrosis induces interleukin-8 gene expression in a human bronchial epithelial cell line. J Clin Invest 1992;89:1478-84.
72. Bernstein PR, Edwards PD, Williams JC. Inhibitors of human leukocyte elastase. In: Ellis GP, Luscombe DK, eds. Progress in medicinal chemistry. Amsterdam: Elsevier, 1994: 59-120.
73. Williams JC, Falcone RC, Knee C, et al. Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase. Am Rev Respir Dis 1991;144:875-83.
74. Kawabata K, Suzuki M, Sugitani M, Imaki K, Toda M, Miyamoto T. ONO-5046, a novel inhibitor of human neutrophil elastase. Biochem Biophys Res Commun 1991; 177:814-20.
75. Sommerhoff CP, Krell RD, Williams JL, Gomes BC, Strimpler AM, Nadel JA. inhibition of human neutrophil elastase by ICI 200,355. Eur Pharmacol 1991;193:153-8.
76. Luisetti M, Sturani C, Sella D, et al. MR889, a neutrophil elastase inhibitor, in patients with chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled clinical trial. Eur Respir J 1996;9:1482-6.
77. Cadene M, Duranton J, North A, Si Tahar M, Chignard M, Bieth JG. Inhibition of neutrophil serine proteinases by suramin. J Biol Chem 1997;272:9950-5.
78. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Ant J Respir Crit Care Med 1994; 150:S160-4.
79. Yao PM, Buhler JM, D'Ortho MP, et al. Expression of matrix metalloproteinase gelatinases A and B by cultured epithelial cells from human bronchial explants. J Biol Chem 1996;271:15580-9.
80. Finlay GA, Russell KJ, McMahon KJ, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997;52:502-6.
81. Finlay GA, O'Driscoll LR, Russell KJ, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997;156:240-7.
82. Shapiro SG, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993; 268:23824-9.
83. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 1996;93:3942-6.
84. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage metalloelastase for cigarette smoke-induced emphysema in mice. Science 1997;277: 2002-4.
85. Cawston TE. Metalloproteinase inhibitors and the prevention of connective tisue breakdown. Pharmacol Ther 1996;70:163-82.
86. Wojtowicz Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15: 61-75.
87. Hubbard RC, Crystal RG. Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route. Lung 1990;168 (Suppl):565-78.
88. 1-antitrypsin treatment for cystic fibrosis. Lancet 1991;337: 392-4.
89. 1-antitrypsin deficiency. Eur Respir J 1997;10:2260-3.
90. Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J. Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am Respir Cell Mol Biol 1994;11:733-41.
91. Campbell EJ, Senior RM, McDonald JM, Cox DW. Proteolysis by neutrophils. Relative importance of cell-substrate contact and oxidative inactivation of proteinase inhibitors in vitro. J Clin Invest 1982;70:845-52.
92. Smith SF, Roberts NA, Guz A, Tetley TD. Compromised inhibition of human lung lavage cell elastases. FEBS Lett 1996;390:187-90.
93. Abbinante-Nissen JM, Simpson LG, Leikauf GD. Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 1995;12:L601-6.
94. Llewellyn Jones CG, Lomas DA, Stockley RA. Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation. Thorax 1994;49:567-72.
95. McElvaney NG, Doujaiji B, Moan MJ, Burnham MR, Wu MC, Crystal RG. Pharmacokinetics of recombinant secretory leukoprotease inhibitor aerosolized to normals and individuals with cystic fibrosis. Am Rev Respir Dis 1993;148:1056-60.
96. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:341-57.
97. Dekhuijzen PNR, Aben KHH, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:813-6.
98. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157 (in press).
99. Roman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64:405-15.
100. Lundback B, Lindstrom M, Jonsson E, Anderson S, van Herwaarden C. Effect of N-acetylcysteine on the decline in lung function in patients with COPD. Eur Respir J 1995;5(Suppl15):895.
101. Thomas CE, Ohlweiler DF, Carr AA, et al. Characterization of the radical trapping activity of a novel series of cyclic nitrone spin traps. J Biol Chem 1996;271:3097-104.
102. Miyajima T, Kotake Y. Spin trapping agent, phenyl N-tert-butyl nitrone, inhibits induction of nitric oxide synthase in endotoxin-induced shock in mice. Biohem Biophys Res Commun 1995;215:114-21.
103. Morrow JD, Roberts LJ. The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 1996;51:1-9.
104. Morrow JD, Frei B, Longmire AW, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-203.
105. 2α, a novel noncyclooxygenase derived prostaglandin, is a potent constrictor of guinea-pig and human airways. Am J Respir Crit Care Med 1996;153:590-6.
106. Tamaoki J, Chiyotani A, Kobayashi S, Noritaka T, Kanemura T, Takizawa T. Effect of indomethacin on bronchorrhea with chronic bronchitis, diffuse panbronchiolitis or bronchiectasis. Am Rev Respir Dis 1992;145:548-52.
107. Llewellyn Jones CG, Johnson MM, et al. In vivo study of indomethacin in bronchiectasis: effect on neutrophil function and lung secretion. Eur Respir J 1995;8:1479-87.
108. Barnes PJ, Liu S. Regulation of pulmonary vascular tone. Physiol Rev 1995;47:87-118.
109. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349:1365.
110. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124:820-4.
111. Pepke Zaba J, Higenbottam TW, Dinh Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991;338:1173-4.
112. Barnes PJ. Endothelins and pulmonary diseases. J Appl Physiol 1994;77:1051-9.
113. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
114. Sofia M, Mormile M, Faraone S, et al. Increased 24-hour endothelin-1 urinary excretion in patients with chronic obstructive pulmonary disease. Respiration 1994;61:263-8.
115. Dicarlo VS, Chen SJ, Meng QC, et al. ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol 1995;269: L690-7.
116. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995;268:H828-35.
117. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995;269:H1186-94.
118. Kiely DG, Cargill RI, Wheeldon NM, Coutie WJ, Lipworth BJ. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. Cardiovasc Res 1997;33:201-8.
119. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996;153: 1530-5.
120. Rogers DF, Aursudkij B, Barnes PJ. Effects of tachykinins on mucus secretion on human bronchi in vitro. Eur J Pharmacol 1989;174:283-6.
121. Kuo H, Rhode JAL, Tokuyama K, Barnes PJ, Rogers DF. Capsaicin and sensory neuropeptide stimulation of goblet cell secretion in guinea pig trachea. J Physiol 1990;431: 629-11.
122. Kuo H, Barnes PJ, Rogers DF. Cigarette smoke-induced airway goblet cell secretion: dose dependent differential nerve activation. Am J Physiol 1992;7:L161-7.
123. Ramnarine SI, Hirayama Y, Barnes PJ, Rogers DF. "Sensory-efferent" neural control of mucus secretion: characterization using tachykinin receptor antagonists in ferret trachea in vitro. Br J Pharmacol 1994;113:1183-90.
124. Ichinose M, Katsumata U, Kikuchi R, et al. Effect of tachykinin receptor antagonist on chronic bronchitis patients. Am Rev Respir Dis 1993;147:A318.
125. Barnes PJ, Belvisi MG, Rogers DF. Modulation of neurogenic inflammation: novel approaches to inflammatory diseases. Trends Pharmacol Sci 1990;11:185-9.
126. Kuo H-P, Rohde J, Barnes PJ, Rogers DF. Differential effects of opioids on cigarette smoke, capsaicin and electrically-induced goblet cell secretion in guinea pig trachea. Br J Pharmacol 1992;105:361-6.
127. Rogers DF, Barnes PJ. Opioid inhibition of neurally mediated mucus secretion in human bronchi : implications for chronic bronchitis therapy. Lancer 1989;i:930-2.
128. 2) (BW 443C) in healthy volunteers. Eur J Clin Pharmacol 1988;34:67-71.
129. Kuo H, Rohde JAL, Barnes PJ, Rogers DF. K+ channel activator inhibition of neurogenic goblet cell secretion in guinea pig trachea. Eur J Pharmacol 1992;221:385-8.
130. Gendler SJ, Spicer AP. Epithelial mucin genes. Annu Rev Physiol 1995;57:607-34.
131. Kai H, Yoshitake K, Hisatsune A, et al. Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am J Physiol 1996;271:L484-8.
132. Shah PL, Scott SF, Knight RA, Marriott C, Ranasinha C, Hodson ME. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996;51:119-25.
133. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990;141:72-8.
134. Tamaoki J, Nakata J, Takeyama K, Chiyotani A, Konno K. Histamine H, receptor-mediated airway goblet cell secretion and its modulation by histamine-degrading enzymes. J Allergy Clin Immunol 1997;99:233-8.
135. Marom ZM, Goswami SK. Respiratory mucus hypersecretion (bronchorrhea): a case discussion - possible mechanisms(s) and treatment. J Allergy Clin Immunol 1991;87:1050-5.
136. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997;155:2018-23.
137. Massaro G, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nature Med 1997;3:675-7.
138. Sandiford AJ, Weir TD, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Eur Respir J 1997; 10:1380-91.
139. Smith CAD, Harrison DJ. Association between polymorphism in gene fro microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997;350:630-3.